@GidMK The 'precision medicine' that referred to choosing mental health drugs based on genetic polymorphisms and what not is and has always been a bust. Precision med in oncology is saving lives already, will only improve more w/ ctDNA Example of trial de
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @TumorBoardTues: 8/9 #TumorBoardTuesday Thursday Case🎀 ✅Consider low-tox chemo upfront in onc emergency- ongoing studies re: other regi…
RT @TumorBoardTues: 8/9 #TumorBoardTuesday Thursday Case🎀 ✅Consider low-tox chemo upfront in onc emergency- ongoing studies re: other regi…
RT @TumorBoardTues: 8/9 #TumorBoardTuesday Thursday Case🎀 ✅Consider low-tox chemo upfront in onc emergency- ongoing studies re: other regi…
8/9 #TumorBoardTuesday Thursday Case🎀 ✅Consider low-tox chemo upfront in onc emergency- ongoing studies re: other regimens ✅NGS can illuminate future options ✅The future: PANGEA- personalized tx w ongoing 🧺trials based on NGS upfront! https://t.co/L672
RT @ShimaghavimiMD: @doctorC369 @TumorBoardTues @DocCatenacci #PANGEA #PrecisionMedicine #TumorBoardTuesday Testing a predefined treatment…
RT @ShimaghavimiMD: @doctorC369 @TumorBoardTues @DocCatenacci #PANGEA #PrecisionMedicine #TumorBoardTuesday Testing a predefined treatment…
RT @ShimaghavimiMD: @doctorC369 @TumorBoardTues @DocCatenacci #PANGEA #PrecisionMedicine #TumorBoardTuesday Testing a predefined treatment…
RT @ShimaghavimiMD: @doctorC369 @TumorBoardTues @DocCatenacci #PANGEA #PrecisionMedicine #TumorBoardTuesday Testing a predefined treatment…
@doctorC369 @TumorBoardTues @DocCatenacci #PANGEA #PrecisionMedicine #TumorBoardTuesday Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: "It's time to start prioritizing biomarkers & their matched therapy in 1L #GEA." #PANGEA study set the precedent. @CD_A…
RT @DocCatenacci: "It's time to start prioritizing biomarkers & their matched therapy in 1L #GEA." #PANGEA study set the precedent. @CD_A…
RT @DocCatenacci: "It's time to start prioritizing biomarkers & their matched therapy in 1L #GEA." #PANGEA study set the precedent. @CD_A…
RT @DocCatenacci: "It's time to start prioritizing biomarkers & their matched therapy in 1L #GEA." #PANGEA study set the precedent. @CD_A…
RT @DocCatenacci: "It's time to start prioritizing biomarkers & their matched therapy in 1L #GEA." #PANGEA study set the precedent. @CD_A…
"It's time to start prioritizing biomarkers & their matched therapy in 1L #GEA." #PANGEA study set the precedent. @CD_AACR https://t.co/hiQBXZzQ4w Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma - ecan
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VivekSubbiah: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease @CD_AACR https://t.co/8wJUrM86Ja
✅Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease | Cancer Discovery https://t.co/rlIPZPcYJY
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an i…
ICYMI in @CD_AACR: Personalized antibodies for #gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease @DocCatenacci @UCCancerCenter #ClinicalTrial #AACR21 https://t.co/lxC6q7Gupe
RT @cancer_evolve: GASTROESOPHAGEAL: the PANGEA umbrella trial added biomarker-stratified monocloncal antibodt therapy (including PD-1, ERB…
GASTROESOPHAGEAL: the PANGEA umbrella trial added biomarker-stratified monocloncal antibodt therapy (including PD-1, ERBB2, EGFR & MET) to standard of care chemotherapy in first line. Response rates and survival were superior to historical controls. ht
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
@FogacciJoao @MayCho_MD @SteveMaronMD @KlempnerSam @jhuynh @UCDHemeOnc Ya b/c that study didn’t confirm HER2+. In pts’ tumors that remain HER2+, I continue antiHer2 tx (my pref is w mFOLFIRI-tras). It is the ~same tx as TDXd, sans ILD & $$$😏 (until pro
RT @CD_AACR: From the February issue— Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an…
RT @CD_AACR: From the February issue— Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an…
RT @DocCatenacci: #Tweetorial8b Case Discussion 2/2 ✅ tumor biopsies can be useful for reassessing tumor biology: 📌 https://t.co/JSwbFO4y…
RT @DocCatenacci: #Tweetorial6️ ✅Recent papers evaluating HER2 conversion show rates of conversion between 15-45%. ✅ The longer the pt is…
RT @DocCatenacci: @MayCho_MD @SteveMaronMD @KlempnerSam @jhuynh @UCDHemeOnc mOS >2years with this strategy in HER2+ from 1L. 👇🏻👇🏻 https://…
@MayCho_MD @SteveMaronMD @KlempnerSam @jhuynh @UCDHemeOnc mOS >2years with this strategy in HER2+ from 1L. 👇🏻👇🏻 https://t.co/hiQBXZzQ4w
RT @CD_AACR: From the February issue— Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an…
From the February issue— Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase 2 study evaluating an individualized treatment strategy for metastatic disease. @DocCatenacci #ClinicalTrial #GastricCancer #EsophagealCancer https://
RT @DocCatenacci: #Tweetorial8b Case Discussion 2/2 ✅ tumor biopsies can be useful for reassessing tumor biology: 📌 https://t.co/JSwbFO4y…
RT @DocCatenacci: #Tweetorial8b Case Discussion 2/2 ✅ tumor biopsies can be useful for reassessing tumor biology: 📌 https://t.co/JSwbFO4y…
RT @DocCatenacci: #Tweetorial6️ ✅Recent papers evaluating HER2 conversion show rates of conversion between 15-45%. ✅ The longer the pt is…
#Tweetorial8b Case Discussion 2/2 ✅ tumor biopsies can be useful for reassessing tumor biology: 📌 https://t.co/JSwbFO4yMm ✅ but so can liquid biopsies be useful for reassessing tumor biology, and may better represent the dz in its entirety: 📌 https://t
#Tweetorial6️ ✅Recent papers evaluating HER2 conversion show rates of conversion between 15-45%. ✅ The longer the pt is on & over more lines of anti-HER2 Rx may increase this finding. 📌 https://t.co/ngRMVHGgkq 📌 https://t.co/JSwbFO4yMm https://t.co/
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
Cool targeted onc/precision medicine paper "This study highlights excellent outcomes achieved by individually optimizing chemo- therapy, biomarker profiling, and matching of targeted therapies at baseline and over time" https://t.co/b2zNRXS9xz
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @VanitaNoronha: Interesting strategy @OncoAlert
Happy to see the final version typeset online now, with beautiful artwork @CD_AACR
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
Congratulations Dan
RT @VanitaNoronha: Interesting strategy @OncoAlert https://t.co/KajSQzWPgS
Interesting strategy @OncoAlert
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
RT @DocCatenacci: Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treat…
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease https://t.co/J9JpKnj1t3
論文はこれ。https://t.co/iWClNud9a3
Read the article here: https://t.co/hXRxXYFaVI
RT @UCHemOncFellows: Check out this article on the PANGEA study featuring multiple @UCCancerCenter including @DocCatenacci and 3rd-year fel…
RT @UCHemOncFellows: Check out this article on the PANGEA study featuring multiple @UCCancerCenter including @DocCatenacci and 3rd-year fel…
Check out this article on the PANGEA study featuring multiple @UCCancerCenter including @DocCatenacci and 3rd-year fellow Dr. Natalie Reizine! https://t.co/WgHYM17Idp https://t.co/Z0J8jQa1cJ